Hyperfine Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Hyperfine hat ein Gesamteigenkapital von $75.6M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $85.4M bzw. $9.8M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$63.20m
Eigenkapital	US$75.64m
Gesamtverbindlichkeiten	US$9.81m
Gesamtvermögen	US$85.44m

Jüngste Berichte zur Finanzlage

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Apr 04

Recent updates

Hyperfine appoints Maria Sainz as President, CEO

Oct 06

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Aug 10

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: HYPRDie kurzfristigen Aktiva des Unternehmens ($79.7M) übersteigen seine kurzfristigen Passiva ($8.8M).

Langfristige Verbindlichkeiten: HYPRDie kurzfristigen Vermögenswerte des Unternehmens ($79.7M) übersteigen seine langfristigen Verbindlichkeiten ($1.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: HYPR ist schuldenfrei.

Schulden abbauen: HYPR hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: HYPR auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: HYPR verfügt über eine ausreichende Liquiditätsreserve für 1.5 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 16.5% pro Jahr abnimmt.

Hyperfine Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Recent updates

Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market

Hyperfine, Inc. Provides Earnings Guidance for the Year 2024

Hyperfine, Inc. to Report Q1, 2024 Results on May 13, 2024

Hyperfine, Inc., Annual General Meeting, Jun 11, 2024

Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study

Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023

Hyperfine, Inc. Completes Enrollment for Hope Pmr Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable Mr. Imaging System

Hyperfine, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Hyperfine, Inc. Announces Executive Changes

Hyperfine, Inc. Provides Earnings Guidance for the Year 2023

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System

Hyperfine, Inc. Announces New Data Regarding the Use of the Swoop System in Stroke Patient Follow-Up

Hyperfine, Inc. Announces Chief Financial Officer Changes

Hyperfine, Inc. Announces Termination of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Hyperfine Names Maria Sainz as Chief Executive Officer, Effective October 24, 2022

Hyperfine appoints Maria Sainz as President, CEO

Consensus forecasts updated

Founder & Vice Chairman recently bought US$442k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Hyperfine, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Hyperfine, Inc. Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients

Hyperfine, Inc. Announces Executive Changes, Effective July 29, 2022

Hyperfine stock plunges 14% as CEO Dave Scott steps down

Founder & Vice Chairman recently bought US$119k worth of stock

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Hyperfine, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Hyperfine, Inc., Annual General Meeting, Jun 08, 2022

Hyperfine, Inc. to Report Q1, 2022 Results on May 11, 2022

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Hyperfine: MR Imaging In A Swoop

Hyperfine, Inc. to Report Q4, 2021 Results on Mar 23, 2022

Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director

Hyperfine, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Hyperfine, Inc. announced a financing transaction

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen